Tenax Therapeutics’ (TENX) “Outperform” Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Monday,RTT News reports.

Separately, Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research report on Monday. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Tenax Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Tenax Therapeutics Stock Performance

Shares of TENX opened at $6.40 on Monday. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.89. The company’s fifty day moving average is $6.44 and its 200 day moving average is $5.21.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of Tenax Therapeutics in the fourth quarter worth about $84,000. Millennium Management LLC bought a new position in shares of Tenax Therapeutics in the fourth quarter worth about $166,000. Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics in the third quarter worth about $101,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics in the third quarter worth about $173,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.